Differential p53-independent outcomes of p19arf loss in oncogenesis Academic Article uri icon


MeSH Major

  • Cyclin-Dependent Kinase Inhibitor p16
  • PTEN Phosphohydrolase
  • Prostatic Neoplasms
  • Tumor Suppressor Protein p53


  • One reported function of the tumor suppressor p19(Arf) is to stabilize p53, providing a critical checkpoint in the response to oncogenic insults. Acute loss of Pten leads to an increase in the abundance of p19(Arf), p53, and p21 proteins as part of a fail-safe senescence response. Here, we report that loss of p19(Arf) in prostate epithelium does not accelerate-but rather partially inhibits-the prostate cancer phenotype of Pten-deficient mice. Moreover, cellular senescence and a further decrease in the number of pre-neoplastic glands were observed in prostates of the Pten-p19(Arf) double-mutant mice. In both prostate epithelium and primary mouse embryo fibroblasts (MEFs), the increase in p53 protein abundance found upon loss of Pten was unaffected by the simultaneous loss of p19(Arf). However, in contrast to that in the prostate epithelium, p19(Arf) deficiency in MEFs lacking Pten abolished cell senescence and promoted hyperproliferation and transformation despite the unabated increase in p53 abundance. Consistent with the effect of p19(Arf) loss in Pten-deficient mouse prostate, we found that in human prostate cancers, loss of PTEN was not associated with loss of p14(ARF) (the human equivalent of mouse p19(Arf)). Collectively, these data reveal differential consequences of p19(Arf) inactivation in prostate cancer and MEFs upon Pten loss that are independent of the p53 pathway.

publication date

  • August 18, 2009



  • Academic Article



  • eng

PubMed Central ID

  • PMC2928478

Digital Object Identifier (DOI)

  • 10.1126/scisignal.2000053

PubMed ID

  • 19690330

Additional Document Info

start page

  • ra44


  • 2


  • 84